Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

His friend Henry Lomb invested his savings in Bausch's shop and in 1855 became his partner. Even with the loan, the business floundered until Bausch stumbled upon a piece of vulcanized rubber on a ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

The Bausch and Lomb Center honors two significant figures in the history of RIT; John J. Bausch and Captain Henry Lomb. With the outbreak of the Civil War in 1861, Henry Lomb enlisted with the ...

Amid swirling speculation, Bausch + Lomb (BLCO), a global leader in the contact lens supply industry, is reportedly exploring ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Bausch + Lomb (BLCO) announced an affiliate has acquired Whitecap Biosciences which is currently developing two innovative therapies for ...

Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...